MARKET

CFRXQ

CFRXQ

Contrafect Corp
OTCPK
0.015
-0.000
-0.66%
Closed 14:02 06/13 EDT
OPEN
0.015
PREV CLOSE
0.015
HIGH
0.015
LOW
0.015
VOLUME
9.03K
TURNOVER
136
52 WEEK HIGH
13.02
52 WEEK LOW
0.012
MARKET CAP
160.57K
P/E (TTM)
-0.0008
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CFRXQ last week (0603-0607)?
Weekly Report · 4d ago
Weekly Report: what happened at CFRXQ last week (0527-0531)?
Weekly Report · 06/03 11:12
Weekly Report: what happened at CFRXQ last week (0520-0524)?
Weekly Report · 05/27 11:17
Weekly Report: what happened at CFRXQ last week (0513-0517)?
Weekly Report · 05/20 11:10
Weekly Report: what happened at CFRXQ last week (0506-0510)?
Weekly Report · 05/13 11:20
Weekly Report: what happened at CFRXQ last week (0429-0503)?
Weekly Report · 05/06 11:27
Weekly Report: what happened at CFRXQ last week (0422-0426)?
Weekly Report · 04/29 11:35
Weekly Report: what happened at CFRXQ last week (0415-0419)?
Weekly Report · 04/22 11:23
More
About CFRXQ
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its CF-301 is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.

Webull offers ContraFect Corp stock information, including OTCPK: CFRXQ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CFRXQ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CFRXQ stock methods without spending real money on the virtual paper trading platform.